RU2733735C2 - Композиции для лечения рака с применением антагонистов, связывающихся с компонентом сигнального пути pd-1, и ингибиторов mek - Google Patents

Композиции для лечения рака с применением антагонистов, связывающихся с компонентом сигнального пути pd-1, и ингибиторов mek Download PDF

Info

Publication number
RU2733735C2
RU2733735C2 RU2017102926A RU2017102926A RU2733735C2 RU 2733735 C2 RU2733735 C2 RU 2733735C2 RU 2017102926 A RU2017102926 A RU 2017102926A RU 2017102926 A RU2017102926 A RU 2017102926A RU 2733735 C2 RU2733735 C2 RU 2733735C2
Authority
RU
Russia
Prior art keywords
alkyl
antibody
antagonist
ser
seq
Prior art date
Application number
RU2017102926A
Other languages
English (en)
Russian (ru)
Other versions
RU2017102926A (ru
RU2017102926A3 (en:Method
Inventor
Мелисса ДЖУНТТИЛА
Original Assignee
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. filed Critical Дженентек, Инк.
Publication of RU2017102926A publication Critical patent/RU2017102926A/ru
Publication of RU2017102926A3 publication Critical patent/RU2017102926A3/ru
Application granted granted Critical
Publication of RU2733735C2 publication Critical patent/RU2733735C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2017102926A 2014-07-15 2015-07-15 Композиции для лечения рака с применением антагонистов, связывающихся с компонентом сигнального пути pd-1, и ингибиторов mek RU2733735C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462024988P 2014-07-15 2014-07-15
US62/024,988 2014-07-15
PCT/US2015/040582 WO2016011160A1 (en) 2014-07-15 2015-07-15 Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors

Publications (3)

Publication Number Publication Date
RU2017102926A RU2017102926A (ru) 2018-08-15
RU2017102926A3 RU2017102926A3 (en:Method) 2018-12-21
RU2733735C2 true RU2733735C2 (ru) 2020-10-06

Family

ID=53783950

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017102926A RU2733735C2 (ru) 2014-07-15 2015-07-15 Композиции для лечения рака с применением антагонистов, связывающихся с компонентом сигнального пути pd-1, и ингибиторов mek

Country Status (17)

Country Link
US (3) US10946093B2 (en:Method)
EP (2) EP3169361B1 (en:Method)
JP (2) JP6673896B2 (en:Method)
KR (1) KR20170026630A (en:Method)
CN (2) CN116617401A (en:Method)
AR (1) AR101210A1 (en:Method)
AU (1) AU2015289672A1 (en:Method)
BR (1) BR112017000672A2 (en:Method)
CA (1) CA2954508A1 (en:Method)
ES (1) ES2742500T3 (en:Method)
IL (2) IL250021B (en:Method)
MX (1) MX2017000546A (en:Method)
PL (1) PL3169361T3 (en:Method)
RU (1) RU2733735C2 (en:Method)
SG (2) SG11201700074YA (en:Method)
WO (1) WO2016011160A1 (en:Method)
ZA (1) ZA201701109B (en:Method)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY193562A (en) 2011-08-01 2022-10-19 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
BR112017000672A2 (pt) 2014-07-15 2017-11-14 Genentech Inc composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
CN108368170B (zh) 2015-07-13 2022-04-15 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
AU2017205089B2 (en) 2016-01-08 2023-10-05 F. Hoffmann-La Roche Ag Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
JP7539231B2 (ja) * 2016-04-07 2024-08-23 ケモセントリクス，インコーポレーテッド Ｐｄ－１阻害剤又はｐｄ－ｌ１阻害剤と組み合わせてｃｃｒ１アンタゴニストを投与することによる腫瘍負荷の低減
CN109195989A (zh) * 2016-05-26 2019-01-11 默克专利股份有限公司 用于癌症治疗的pd-1/pd-l1抑制剂
RU2018146886A (ru) * 2016-06-10 2020-07-10 Новартис Аг Пути терапевтического применения ингибитора c-raf
JP7304287B2 (ja) * 2016-12-22 2023-07-06 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
CN108503691B (zh) * 2017-02-25 2021-07-23 复旦大学 一种人pd-l1蛋白高亲和性肽及其应用
BR112019021680A2 (pt) 2017-04-20 2020-05-12 Adc Therapeutics Sa Terapia de combinação com conjugado anticorpo-fármaco anti-cd25??
CA3057748A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
US11951166B2 (en) 2017-06-02 2024-04-09 Bayer Aktiengesellschaft Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
WO2018229222A1 (en) 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc
WO2019023786A1 (en) 2017-08-01 2019-02-07 University Health Network COMBINED THERAPIES FOR THE INHIBITION OF TTK PROTEIN KINASE
MX2020003361A (es) * 2017-10-13 2020-07-29 Merck Patent Gmbh Combinacion de un inhibidor parp y un antagonista de union al eje pd-1.
AU2018401608A1 (en) * 2018-01-10 2020-07-16 Array Biopharma Inc. Methods and combination therapy to treat cancer
CN113286616A (zh) 2018-05-23 2021-08-20 Adc治疗有限公司 分子佐剂
CN119955743A (zh) * 2018-09-10 2025-05-09 上海锦斯生物技术有限公司 修饰的溶瘤病毒、其组合物和用途
CN109053891B (zh) 2018-09-17 2021-12-21 苏州泓迅生物科技股份有限公司 一种抗pd-l1抗体及其制备方法和应用
CN109879855B (zh) * 2019-03-26 2021-01-05 中国医学科学院医药生物技术研究所 靶向肿瘤细胞表面pd-l1分子的抑制剂及其应用
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
CN110981943B (zh) * 2019-12-02 2021-08-03 清华大学 多肽及其在制备药物中的用途和药物
EP4178573A4 (en) * 2020-07-13 2024-08-07 Verastem, Inc. COMBINATION THERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
AU2022320304A1 (en) * 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013019906A1 (en) * 2011-08-01 2013-02-07 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
WO1984003506A1 (en) 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5571689A (en) 1988-06-16 1996-11-05 Washington University Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69128350T2 (de) 1990-06-11 1998-03-26 Nexstar Pharmaceuticals Inc Nukleinsäureliganden
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0558671T3 (da) 1990-11-21 1999-09-13 Iterex Pharma Lp Syntese af ækvimolære multiple oligomerblandinger, især af oligopeptidblandinger
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
JP4460155B2 (ja) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
AU8856201A (en) 2000-09-01 2002-03-13 Andel Inst Van Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US20030232869A1 (en) 2002-03-13 2003-12-18 Wallace Eli M. N3 alkylated benzimidazole derivatives as MEK inhibitors
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2502413A1 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
WO2004045617A1 (en) 2002-11-15 2004-06-03 Warner-Lambert Company Llc Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
RS52670B (sr) 2004-06-11 2013-06-28 Japan Tobacco Inc. Derivati 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2h-pirido(2,3-d)pirimidina i slična jedinjenja za lečenje kancera
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
CN103059138B (zh) 2005-05-09 2015-10-28 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
NZ564592A (en) 2005-07-01 2011-11-25 Medarex Inc Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
ES2365070T3 (es) 2005-10-07 2011-09-21 Exelixis, Inc. Azetidinas com inhibidores de mek para el tratamiento de enfermedades proliferativas.
US7612212B2 (en) 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
ES2376771T3 (es) 2006-08-21 2012-03-16 Genentech, Inc. Compuestos aza-benzofuranilo y métodos de utilización
WO2008101840A1 (en) 2007-02-23 2008-08-28 F. Hoffmann-La Roche Ag Combination of erlotinib and mek-inhibitors for inhibiting proliferation of tumor cells
ES2383927T3 (es) 2007-08-16 2012-06-27 F. Hoffmann-La Roche Ag Hidantoínas sustituidas
CA2705452C (en) 2007-11-12 2016-05-31 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
US20110085970A1 (en) 2007-11-30 2011-04-14 Terrett Jonathan A Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
SI2690101T1 (sl) 2007-12-19 2015-10-30 Genentech, Inc. 5-anilinoimidazopiridini in postopki za uporabo
BRPI0907718A2 (pt) 2008-02-11 2017-06-13 Curetech Ltd método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento
JP2011513331A (ja) 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤
ES2392482T3 (es) 2008-02-29 2012-12-11 Array Biopharma, Inc. Derivados de imidazo[4,5-b] piridina usados como inhibidores de RAF
US20110003859A1 (en) 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
MX2010009410A (es) 2008-02-29 2010-11-30 Array Biopharma Inc Compuestos del inhibidor de raf y métodos de uso de los mismos.
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CN102089007B (zh) 2008-07-11 2013-05-15 诺瓦提斯公司 (a)磷酸肌醇3-激酶抑制剂和(b)ras/raf/mek通路调节剂的组合产品
KR20110074850A (ko) 2008-08-25 2011-07-04 앰플리뮨, 인크. Ｐｄ-１ 길항제 및 그의 사용 방법
MX2011002252A (es) 2008-08-25 2011-06-24 Amplimmune Inc Composiciones de antagonistas del pd-1 y metodos de uso.
WO2010056735A1 (en) 2008-11-11 2010-05-20 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting an oncogenic protein to enhance immunogenicity
MX2011005853A (es) 2008-12-09 2011-08-04 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
BR112012008483A2 (pt) 2009-10-12 2019-09-24 Hoffmann La Roche combunações de um inibidor de pi3k e um inibidor de mex
EP2501237A1 (en) 2009-11-06 2012-09-26 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor
EP2499486A4 (en) 2009-11-13 2013-11-27 Infinity Pharmaceuticals Inc COMPOSITIONS, KITS AND METHODS OF IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CANCER
AU2010324757C1 (en) 2009-11-24 2018-05-17 Medimmune Limited Targeted binding agents against B7-H1
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
KR101828570B1 (ko) 2010-03-04 2018-02-13 마크로제닉스, 인크. Ｂ７―ｈ３에 반응성인 항체, 면역학적으로 활성인 이들의 단편 및 이들의 사용법
WO2013063001A1 (en) 2011-10-28 2013-05-02 Genentech, Inc. Therapeutic combinations and methods of treating melanoma
BR112015022019A2 (pt) 2013-03-14 2017-08-29 Genentech Inc Anticorpos isolados, ácido nucleico, célula hospedeira, método de produção de anticorpos, imunoconjugado, formulação farmacêutica, métodos de tratamento de indivíduos, de inibição da proliferação de células, de detecção de b7-h4 humano e de detecção de câncer
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
RU2015154275A (ru) 2013-06-03 2017-07-17 Новартис Аг Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf
BR112017000672A2 (pt) 2014-07-15 2017-11-14 Genentech Inc composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013019906A1 (en) * 2011-08-01 2013-02-07 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JIANG X et al. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res., 2013, 19(3), p.598-609. VELLA LJ et al. The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations. Oncoimmunology, 03.07.2014, 3(7), e946367. *
JIANG X et al. The activation of MAPK in melanoma cells resistant to BRAF inhibitionpromotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin CancerRes., 2013, 19(3), p.598-609. *
MENZIES AM et al. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. Eur J Cancer., 2013, 49(15), р.3229-41. *
VELLA LJ et al. The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations. Oncoimmunology, 03.07.2014, 3(7),e946367. *

Also Published As

Publication number Publication date
CA2954508A1 (en) 2016-01-21
PL3169361T3 (pl) 2019-11-29
KR20170026630A (ko) 2017-03-08
ZA201701109B (en) 2021-07-28
CN116617401A (zh) 2023-08-22
EP3169361B1 (en) 2019-06-19
JP2020059721A (ja) 2020-04-16
CN106573060A (zh) 2017-04-19
RU2017102926A (ru) 2018-08-15
RU2017102926A3 (en:Method) 2018-12-21
EP3563870A1 (en) 2019-11-06
US20170112925A1 (en) 2017-04-27
US10946093B2 (en) 2021-03-16
ES2742500T8 (es) 2020-02-27
BR112017000672A2 (pt) 2017-11-14
EP3169361A1 (en) 2017-05-24
JP2017522307A (ja) 2017-08-10
AU2015289672A1 (en) 2017-03-02
ES2742500T3 (es) 2020-02-14
JP6673896B2 (ja) 2020-03-25
MX2017000546A (es) 2017-03-08
SG10202007111TA (en) 2020-09-29
SG11201700074YA (en) 2017-02-27
US20220105180A1 (en) 2022-04-07
WO2016011160A1 (en) 2016-01-21
IL250021B (en) 2020-08-31
IL250021A0 (en) 2017-03-30
US20240390488A1 (en) 2024-11-28
AR101210A1 (es) 2016-11-30
IL276314A (en) 2020-09-30

Similar Documents

Publication Publication Date Title
RU2733735C2 (ru) Композиции для лечения рака с применением антагонистов, связывающихся с компонентом сигнального пути pd-1, и ингибиторов mek
US10646567B2 (en) Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
HK40098545A (zh) 使用pd-1轴结合拮抗剂和mek抑制剂治疗癌症的组合物
HK1233170A1 (en) Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
HK1196321B (en) Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
HK1196321A (en) Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
NZ620411B2 (en) Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors